Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (pu… Read more
Modus Therapeutics Holding AB (MODTX) - Total Liabilities
Latest total liabilities as of December 2025: Skr3.62 Million SEK
Based on the latest financial reports, Modus Therapeutics Holding AB (MODTX) has total liabilities worth Skr3.62 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Modus Therapeutics Holding AB - Total Liabilities Trend (2018–2025)
This chart illustrates how Modus Therapeutics Holding AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Modus Therapeutics Holding AB Competitors by Total Liabilities
The table below lists competitors of Modus Therapeutics Holding AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KIMBERLY-CLARK
BE:KMY
|
Germany | €15.72 Billion |
|
Asia Pptys Inc
PINK:ASPZ
|
USA | $160.17K |
|
Solis Minerals Ltd
PINK:SLMFF
|
USA | $2.43 Million |
|
AMEDISYS
BE:ADY
|
Germany | €938.67 Million |
|
Exro Technologies Inc
OTCQB:EXROF
|
USA | $164.97 Million |
|
Silicon Gaming Inc
PINK:SGIC
|
USA | $-3.51 Million |
|
Flexituff Ventures International Limited
NSE:FLEXITUFF
|
India | ₹4.67 Billion |
|
UNITED PARCEL SVC-B - Dusseldorf Stock Exchang
DU:UPAB
|
Germany | €51.38 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Modus Therapeutics Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Modus Therapeutics Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Modus Therapeutics Holding AB (2018–2025)
The table below shows the annual total liabilities of Modus Therapeutics Holding AB from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr3.62 Million | +31.60% |
| 2024-12-31 | Skr2.75 Million | +16.45% |
| 2023-12-31 | Skr2.36 Million | -82.97% |
| 2022-12-31 | Skr13.86 Million | +153.96% |
| 2021-12-31 | Skr5.46 Million | +1000.00% |
| 2020-12-31 | Skr496.00K | -89.53% |
| 2019-12-31 | Skr4.74 Million | -79.45% |
| 2018-12-31 | Skr23.05 Million | -- |